XTL develops hepatitis method
A new type of treatment developed by XTL Biopharmaceuticals, the London listed Israeli biotechnology company could make hepatitis treatment much more effective according to preliminary trial data
Related Content
- SNBNCBS develops a “No-touch” &“Painless” device for non-invasive screening of bilirubin level in newborns
- Development of a simple noninvasive model to predict significant fibrosis in patients with chronic Hepatitis B: Combination of ultrasound elastography, serum biomarkers, and individual characteristics
- Study on prevalence of Hepatitis C infection in healthy and high risk groups
- Saliva test
- Miracle medicine
- Woes of the world